Search

Combinations of different therapeutic strategies, including chemotherapy (CT), chemodynamic therapy (CDT), and photothermal therapy (PTT), are needed to effectively address evolving drug resistance and the adverse effects of traditional cancer treatment. Herein, a camouflage composite nanoformulation (TCBG@PR), an antitumor agent (tubercidin, Tub) loaded into Cu-doped bioactive glasses (CBGs) and subsequently camouflaged by polydopamine (PDA), and red blood cell membranes (RBCm), was successfully constructed for targeted and synergetic antitumor therapies by combining CT of Tub, CDT of doped copper ions, and PTT of PDA. In addition, the TCBG@PRs composite nanoformulation was camouflaged with a red blood cell membrane (RBCm) to improve biocompatibility, longer blood retention times, and excellent cellular uptake properties. It integrated with long circulation and multimodal synergistic treatment (CT, CDT, and PTT) with the benefit of RBCms to avoid immune clearance for efficient targeted delivery to tumor locations, producing an “all-in-one” nanoplatform. In vivo results showed that the TCBG@PRs composite nanoformulation prolonged blood circulation and improved tumor accumulation. The combination of CT, CDT, and PTT therapies enhanced the antitumor therapeutic activity, and light-triggered drug release reduced systematic toxicity and increased synergistic antitumor effects.

Allopurinol (AP) is widely used to treat hyperuricemia which may cause severe side effects upon oral administration. Alternative means for the treatment of hyperuricemia are demanded to simultaneously facilitate drug absorption, patient compliance, and fewer side effects. In this study, a new polymer microneedle (MN) system was developed for the transdermal delivery of AP to acute hyperuricemic mice. This study aims to achieve the controllable regulation of serum uric acid (SUA) levels with fewer side effects compared with oral administration. The matrix of polymer MNs consisted of polyvinylpyrrolidone (PVP) and polycaprolactone (PCL), in which the rapid dissolution of PVP offers a rapid dissolution of AP into the blood and the biodegradability of PCL resulting in a sustainable drug release behavior. An in vivostudy demonstrated that the AP-loaded MN system can effectively reduce the SUA levels as oral administration with lower side effects, which will be conducive to reducing the adverse reactions and improving the bioavailability of AP. This MN-mediated strategy can facilitate transcutaneous hyperuricemia treatment and provide a new alternative for the exploration of clinical treatment of hyperuricemia and improvement of patient compliance.

Skin ulcers are one of the complications of diabetes. At present, the treatment of diabetic skin wounds is still not satisfactory, and the efficiency of drug delivery is limited by the depth of penetration. Herein, a synergistically flexible microneedle dressing is presented for effectively promoting diabetic wound healing. Metformin, as an anti-diabetic drug, can be loaded into microneedles, which can effectively pierce into the skin of diabetic rats to trigger a response for regulating blood glucose levels. A novel multifunctional nanosystem CaO2@polydopamine (CaO2@PDA) was introduced into polycaprolactone and gelatin (PCL/Gel) electrospun nanofiber films as microneedle back patches to inhibit inflammation, provide oxygen, and absorb the excess exudate. Besides, the CaO2@PDA in back patches also provided effective antibacterial properties against both S. aureusand E. coli. Additionally, the as-fabricated flexible microneedle dressings loaded with metformin and CaO2@PDA nanoparticles demonstrated a high level of CD31 and low level of TNF-α, leading to accelerated diabetic skin-wound closure. These distinctive features demonstrate that our microneedle system can be a facile candidate for efficient wound healing in patients with diabetes and may be applied in various biomedical fields.